212. Back to Basics - Non-Melanoma Skin Cancer

If you like cemiplimab, you will like this episode. Since its introduction, cemiplimab has become the mainstay of treatment for cutaneous SCC, the most common non-melanoma skin cancer likely to attend an oncologist. Cemiplimab's scope is expanding; once reserved purely for the locally advanced or metastatic setting, evidence is emerging for its efficacy in the neoadjuvant setting. Today, Josh and Michael explore the use cases for cemiplimab in cSCCNOTE: this episode was NOT sponsored by cemiplimab!Studies Discussed in Today's EpisodeMigden et al. (2018)Gross et al (2023)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.